Beam Therapeutics

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby DNA sequences can be modified even more precisely compared to previous methods.[1][2]

Beam Therapeutics Inc.
TypePublic company
ISINUS07373V1052
IndustryBiotechnology
Founded2017 (2017)
Founders
HeadquartersCambridge, Massachusetts, U.S.
Number of employees
306 (September 30, 2021)
Websitebeamtx.com

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[3] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors.[4] In a February 2020 IPO, the company raised $180 million.[5] The first clinical trials for therapies are expected in 2021.[6]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[7][8]

See also

References
  1. "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Archived from the original on 2021-08-07.
  2. Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
  3. Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
  4. Sewell, Dawson; Burns, Joe; Villarisco, Julius John; Faraguna, Carla; Ogolla, Henry; Gomila, Jude; Scherfner, Erin; Hammond, Rebecca; Solanki, Bhupendra. "Beam Therapeutics". Golden. Archived from the original on 2020-08-08. Retrieved 2021-07-08.
  5. Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
  6. Philippidis, Alex (2020-02-06). "Beam Therapeutics, Base Editing Drug Developer, Raises $180M in IPO". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-07-08.
  7. "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". Pfizer.
  8. Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases". www.barrons.com. Retrieved 2022-02-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.